Targeting and therapeutic peptide-based strategies for polycystic kidney disease

Jonathan Wang; Nirmalya Tripathy; Eun Ji Chung

doi:10.1016/j.addr.2020.08.011

Targeting and therapeutic peptide-based strategies for polycystic kidney disease

Adv Drug Deliv Rev. 2020:161-162:176-189. doi: 10.1016/j.addr.2020.08.011. Epub 2020 Aug 29.

Authors

Jonathan Wang¹, Nirmalya Tripathy¹, Eun Ji Chung²

Affiliations

¹ Department of Biomedical Engineering, University of Southern California, Los Angeles, CA, USA.
² Department of Biomedical Engineering, University of Southern California, Los Angeles, CA, USA; Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, CA, USA; Department of Medicine, Division of Nephrology and Hypertension, University of Southern California, Los Angeles, CA, USA; Department of Surgery, Division of Vascular Surgery and Endovascular Therapy, University of Southern California, Los Angeles, CA, USA. Electronic address: eunchung@usc.edu.

Abstract

Polycystic kidney disease (PKD) is characterized by progressive cyst growth and is a leading cause of renal failure worldwide. Currently, there are limited therapeutic options available to PKD patients, and only one drug, tolvaptan, has been FDA-approved to slow cyst progression. Similar to other small molecule drugs, however, tolvaptan is costly, only moderately effective, and causes adverse events leading to high patient dropout rates. Peptides may mitigate many drawbacks of small molecule drugs, as they can be highly tissue-specific, biocompatible, and economically scaled-up. Peptides can function as targeting ligands that direct therapies to diseased renal tissue, or be potent as therapeutic agents themselves. This review discusses various aberrant signaling pathways in PKD and renal receptors that can be potential targets of peptide-mediated strategies. Additionally, peptides utilized in other kidney applications, but may prove useful in the context of PKD, are highlighted. Insights into novel peptide-based solutions that have potential to improve clinical management of PKD are provided.

Keywords: Chronic kidney disease; Peptide; Polycystic kidney disease; Targeted drug delivery.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Disease Progression
Drug Delivery Systems / methods*
Humans
Kidney / physiology*
Peptides / administration & dosage*
Polycystic Kidney Diseases / drug therapy*
Polycystic Kidney Diseases / physiopathology*
Signal Transduction

Substances

Peptides

Abstract

Publication types

MeSH terms

Substances

Grants and funding